Pamplona Capital Management has agreed to acquire Parexel International (Nasdaq: PRXL), a Boston-area contract drug research organization, for approximately $5 billion (including debt). The $88.10 per share price represents around a 5% premium to yesterday's closing price, but nearly a 28% premium to where the stock was trading in May before the first reports of a sale process emerged.

  • Why it matters: This is one of the rare cases where private equity beat out strategics on a multi-billion dollar deal, with both LabCorp and ICON reportedly having submitted bids. Let alone against an Ireland-based company like ICON, which can build sorts of tax advantages into its bid. It's also just the latest example of activist investor success, as groups like Starboard Value had been agitating for a sale.
  • Bottom line: "Parexel has just under 20,000 employees and made $605 million in revenue in the March quarter, according to its financials. But has been in the process of slimming down, as the CRO has had several rounds of job cuts since it dialed down its 2016 outlook in 2015. Those include 850 jobs announced 2015, in order to save about $20 million to $30 million a year from 2016, plus 1,100 to 1,200 worldwide announced just a few months ago, amid the buyout rumors." — Ben Adams, FierceBiotech

Go deeper

Exclusive: The N.Y. Times doubles down on TV and film ambitions

Illustration: Aïda Amer/Axios

One of the country's oldest and most established media companies is starting to look more like a Hollywood studio than a traditional newspaper.

Driving the news: The New York Times has 10 scripted TV show projects in development, as well as 3 feature documentaries coming out this year and several other documentary projects in development and production, executives tell Axios.

Electric vehicle companies are reeling in cash without producing a car

Illustration: Sarah Grillo/Axios

These are heady days for electric vehicle companies, with a lack of actual car production becoming a popular norm.

Why it matters: The capital infusion is the latest in a busy stretch of deals and market moves that suggest private investors and equity markets see big potential in technologies that now represent a tiny slice of the global vehicle fleet.

Updated 1 hour ago - Politics & Policy

Federal government carries out first execution since 2003

Lethal injection facility in San Quentin, California. Photo: California Department of Corrections and Rehabilitation via Getty Images

The first execution carried out by the federal government since 2003 took place on Tuesday at a federal prison in Indiana after an early-morning Supreme Court decision allowed it to move forward, the Washington Post reports.

The big picture: A lower court had delayed the execution, saying inmates had provided evidence the government's plan to carry out executions using lethal injections "poses an unconstitutionally significant risk of serious pain."